The original disclosure in Japanese was released on July 27, 2017 at 15:30 (GMT+9)

Consolidated Financial Statements for the First Quarter Ended June 30, 2017
FY2018 (April 1, 2017 - March 31, 2018) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: http://www.takara.co.jp/
Company representative: Toshio Kakimoto, President
Contact: Takuya Kakemi, General Manager of Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date (as planned): August 8, 2017

Notes:
1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the three months ended June 30, 2017 (April 1, 2017 - June 30, 2017)

(1) Operating results

Note: Percentages indicated changes from the previous fiscal year.

	Three months ended June 30, 2017		Three months ended June 30, 2016	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	63,368	21.1	52,311	2.7
Operating income (loss)	2,074	27.3	1,630	151.0
Ordinary income (loss)	2,247	12.4	1,998	88.3
Net income (loss) attributable to owners of the parent	1,163	7.3	1,084	63.7
Net income (loss) per share (Yen)	5.78		5.39	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income	171	-	(3,242)	-

(2) Financial position

	As of June 30, 2017	As of March 31, 2017
	(Millions of yen)	(Millions of yen)
Total assets	280,443	274,368
Net assets	163,099	165,920
Equity ratio (%)	47.5	49.2
(Reference) Equity	133,088	135,043

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2017	Year ending March 31, 2018	Year ending March 31, 2018 (Forecast)
First quarter end	-	-	
Second quarter end	-		-
Third quarter end	-		-
Year end	13.00		14.00
Annual	13.00		14.00

Note: Correction of dividend forecast from the most recent dividend forecast : No

3. Forecast for the year ending March 31, 2018 (April 1, 2017 - March 31, 2018)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2017		Year ending March 31, 2018	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	125,000	16.3	268,000	14.4
Operating income (loss)	4,700	(9.7)	14,000	3.3
Ordinary income (loss)	4,700	(16.3)	14,400	0.4
Net income (loss) attributable to owners of the parent	2,400	(24.5)	8,500	0.2
Net income per share (Yen)	11.93		42.24	

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

(1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change is subsidiaries) : Yes
Newly included: 2 (Name) WaferGen Bio-systems, Inc., Rubicon Genomics, Inc.
Excluded: 1 (Name) Rubicon Genomics, Inc.

(2) Applying of specific accounting of the consolidated quarterly financial statements : No

(3) Changes in accounting policies, accounting estimates and retrospective restatement
1) Changes based on revisions of accounting standard : No
2) Changes other than ones based on revisions of accounting standard : No
3) Changes in accounting estimates : No
4) Restatement : No

(4) Number of outstanding shares (common stock)
1) Number of outstanding shares at year end (Treasury stocks are included)
As of June 30, 2017 : 217,699,743
As of March 31, 2017 : 217,699,743
2) Number of treasury stocks at year end
As of June 30, 2017 : 16,475,746
As of March 31, 2017 : 16,475,431
3) Average number of outstanding shares
Three months ended June 30, 2017 : 201,224,001
Three months ended June 30, 2016 : 201,224,342

Contents of the attached document

1. Qualitative Information for the Three Months Ended June 30, 2017---------- 2
   (1) Consolidated Financial Results ---------- 2
   (2) Consolidated Financial Position ---------- 3
   (3) Qualitative Information Regarding Consolidated Forecasts ---------- 3
2. Consolidated Quarterly Financial Statements and Primary Notes ---------- 6
   (1) Consolidated Quarterly Balance Sheets ---------- 6
   (2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income (For the Three Months Ended June 30, 2017and 2016) ---------- 8
   Consolidated Quarterly Statements of Income (For the Three Months Ended June 30, 2017 and 2016) --- 8
   Consolidated Quarterly Statements of Comprehensive Income (For the Three Months Ended June 30, 2017 and 2016) ---------- 9
   (3) Notes on Consolidated Quarterly Financial Statements ---------- 10
   (Notes on Premise of Going Concern) ---------- 10
   (Notes on Material Changes in Shareholders' Equity) ---------- 10
   (Material Changes in Subsidiaries during the Three Months Ended June 30, 2017) ---------- 10
   (Segment Information) ---------- 10

Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Three Months Ended June 30, 2017

(1) Consolidated Financial Results

In the three months ended June 30, 2017, although the Japanese economy maintained a moderate recovery as the corporate earnings and hiring environment improved, personal spending remained weak.

On the other hand, overseas, the global economy continued to be uncertain due to issues such as the uncertainty in emerging economies, the Brexit matter in the U.K., and the effects of future policies in the U.S.

Under these economic circumstances, in fiscal 2018, the Company initiated the Takara Group Medium-Term Management Plan FY2020, as the last step towards achieving its long-term Takara Group Vision 2020. By further increasing the overseas sales ratio together with having a full product line-up and many products with a competitive edge both in Japan and overseas, the Company is aiming to build up a great number of fields in which it can beat competitors and establish a balanced business foundation able to grow revenues significantly no matter what environmental changes occur.

As a result, in the three months ended June 30, 2017, net sales were up 21.1% year on year to ¥63,368 million. Gross profit rose 17.9% year on year to ¥24,662 million. Operating income increased by 27.3% year on year to ¥2,074 million. Ordinary income increased by 12.4% year on year to ¥2,247 million. Net income attributable to owners of the parent increased by 7.3% to ¥1,163 million.

Results by business segment were as follows.

In accordance with the spinning off of the overseas business of Takara Shuzo Co., Ltd. on July 3, 2017 and the establishment of Takara Shuzo International Co., Ltd., the Company changed its reporting segments starting from the three months ended June 30, 2017, and the year on year comparisons below compare the figures for the same period of the previous fiscal year reclassified into the post-change segments.

[Takara Shuzo]

For alcoholic beverages, in the three months ended June 30, 2017, while sales of shochu were in line with the same period of the previous fiscal year, sales of sake, where *Sho Chiku Bai Ten* performed well, and sales of light-alcohol refreshers, where *Takara Shochu High Ball* remained robust, rose, and sales of alcoholic beverages overall increased.

In the Seasonings Business, sales increased due to healthy sales of mirin and cooking sake while sales of raw alcohol and other products were also up.

As a result, net sales for the Takara Shuzo Group rose 5.2% year on year to ¥36,029 million. Cost of sales increased by 4.2% to ¥21,665 million. As a result, gross profit rose 6.9% year on year to ¥14,363 million. SG&A expenses were up by 5.1% year on year to ¥14,212 million due to increases in promotion expenses and transportation expenses. Accordingly, the Takara Shuzo Group recorded operating income of ¥151 million (operating loss of ¥85 million in the same period of the previous fiscal year).

[Takara Shuzo International Group]

In the three months ended June 30, 2017, sales in the Japanese food wholesale business in overseas markets increased with the contribution of sales from Mutual Trading Co., Inc. (U.S.), which became a consolidated subsidiary at the end of the third quarter of the previous fiscal year, and other companies. As a result, net sales for the Takara Shuzo International Group increased by 121.3% year on year to ¥16,450 million. Cost of sales increased by 134.2% year on year to ¥11,683 million. As a result, gross profit rose by 95.1% year on year to ¥4,767 million. SG&A expenses were up by 107.2% year on year to ¥3,807 million due to an increase in personnel expenses. Accordingly, the Takara Shuzo International Group recorded operating income up 58.4% year on year to ¥960 million.

[Takara Bio Group]

Net sales for the three months ended June 30, 2017 were roughly in line with the same period of the previous fiscal year up by 0.8% year on year to ¥6,355 million as sales of contract services greatly exceeded those of the same period of the previous fiscal year although sales of mainstay research reagents fell year on year due to the influence of the strong yen. As to cost of sales, the cost rate decreased by 8% year on year to ¥2,245 million due to changes in the structure of sales for each product and other factors and, consequently, gross profit increased by 6.3% year on year to ¥4,109 million. Selling, general and administrative (SG&A) expenses increased by 19.4% year on year to ¥3,846 million due to increases in in R&D expenses, personnel costs, and other factors. Accordingly, operating income declined 59.2% year on year to ¥262 million.

[Other]

Net sales of business segments other than the reported segments for the three months ended June 30, 2017 increased by 5.6% year on year to ¥9,634 million as sales in the transportation business and other businesses were healthy overall. Cost of sales increased by 2.6% to ¥8,000 million. Consequently, gross profit increased by 23.6% year on year to ¥1,634

million. SG&A expenses were down by 2.5% to ¥880 million. As a result, operating income up by 79.6% year on year to ¥753 million was recorded.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2016, to June 30, 2016)	Period under Review (from April 1, 2017, to June 30, 2017)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo			
Shochu	13,987	14,089	100.7
Sake	3,888	4,214	108.4
Light-alcohol refreshers	7,364	8,469	115.0
Other alcoholic beverages	1,722	1,641	95.3
Alcoholic beverages total	26,963	28,415	105.4
Hon Mirin	3,327	3,359	101.0
Other seasonings	2,175	2,306	106.0
Seasonings total	5,502	5,666	103.0
Raw alcohol, etc.	1,769	1,947	110.1
Total	34,235	36,029	105.2
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	2,264	2,340	103.4
Japanese Food Wholesales Business in overseas markets	5,311	14,516	273.3
Elimination of intra-Group transaction on consolidation	(142)	(406)	-
Total	7,432	16,450	221.3
Takara Bio Group	6,306	6,355	100.8
Reported segment total	47,974	58,835	122.6
Other	9,121	9,634	105.6
Segment total	57,095	68,470	119.9
Sales not allocated to business segments and intersegment transactions	(4,784)	(5,101)	-
Total	**52,311**	**63,368**	**121.1**

Note: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

As of June 30, 2017, current assets were ¥166,758 million, a decrease of ¥7,153 million compared with that at the end of the previous fiscal year. This was primarily due to a decrease in cash and deposits of ¥15,749 million and an increase in securities of ¥6,333 million.

Non-current assets were ¥113,684 million, an increase of ¥13,228 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in intangible assets of ¥12,451 million.

As a result, total assets were ¥280,443 million, an increase of ¥6,074 million compared with that at the end of the previous fiscal year.

As of June 30, 2017, current liabilities were ¥58,804 million, a decrease of ¥6,701 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in current portion of bonds of ¥5,000 million and income taxes payable of ¥1,037 million. Non-current liabilities were ¥58,539 million, an increase of ¥15,597 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in bonds payable of ¥15,514 million.

As a result, total liabilities were ¥117,344 million, an increase of ¥8,896 million compared with that at the end of the previous fiscal year.

As of June 30, 2017, total net assets were ¥163,099 million, a decrease of ¥2,821 million compared with that at the end of the previous fiscal year. This was primarily due to decreases of ¥1,452 million in retained earnings and ¥1,716 million in foreign currency translation adjustments.

As a result, the equity ratio totaled 47.5%, compared with 49.2% at the end of the previous fiscal year.

(3) Qualitative Information Regarding Consolidated Forecasts

The consolidated performance for the three months ended June 30, 2017 exceeded initial forecasts. Nevertheless, the Company has not revised the consolidated forecasts for the six months ending September 30, 2017 or for the fiscal year ending March 31, 2018 that were released on May 9, 2017 because the proportion of the Group's annual income accounted for by income in the first quarter of the fiscal year is relatively low.

2. Consolidated Quarterly Financial Statements

(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2017	As of June 30, 2017
Assets		
Current assets		
Cash and deposits	58,073	42,324
Notes and accounts receivable-trade	57,951	57,682
Securities	13,237	19,571
Merchandise and finished goods	35,300	36,202
Work in process	1,244	1,399
Raw materials and supplies	3,306	3,428
Other	5,035	6,418
Allowance for doubtful accounts	(236)	(266)
Total current assets	173,912	166,758
Noncurrent assets		
Property, plant and equipment	59,174	58,685
Intangible assets		
Goodwill	6,626	13,902
Other	3,630	8,805
Total intangible assets	10,256	22,707
Investments and other assets		
Investment securities	25,583	27,017
Other	5,533	5,364
Allowance for doubtful accounts	(90)	(90)
Total investments and other assets	31,025	32,291
Total noncurrent assets	100,456	113,684
Total assets	274,368	280,443

(Millions of Yen)

	As of Mar. 31, 2017	As of June 30, 2017
Liabilities		
Current liabilities		
Notes and accounts payable-trade	16,804	16,258
Short-term loans payable	9,206	9,084
Current portion of bonds	10,000	5,000
Accrued alcohol tax	7,593	7,568
Accrued expenses	5,562	4,629
Income taxes payable	2,468	1,431
Provision for bonuses	2,449	3,540
Other provision	2,002	2,483
Other	9,418	8,807
Total current liabilities	65,506	58,804
Noncurrent liabilities		
Bonds payable	10,000	25,514
Long-term loans payable	10,996	10,940
Net defined benefit liability	8,961	8,911
Long-term deposits received	5,342	5,324
Other	7,640	7,847
Total noncurrent liabilities	42,941	58,539
Total liabilities	108,447	117,344
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	1,650	1,803
Retained earnings	119,729	118,277
Treasury stock	(9,939)	(9,939)
Total shareholders' equity	124,667	123,367
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	9,583	10,515
Deferred gains or losses on hedges	0	121
Foreign currency translation adjustment	1,426	(290)
Remeasurements of defined benefit plans	(634)	(625)
Total accumulated other comprehensive income	10,375	9,720
Noncontrolling interests	30,877	30,010
Total net assets	165,920	163,099
Total liabilities and net assets	274,368	280,443

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income

(Consolidated Statements of Income)
(For the Three Months Ended June 30, 2017 and 2016)

(Millions of Yen)

	FY2017 (Apr. 1, 2016 – June 30, 2016)	FY2018 (Apr. 1, 2017 – June 30, 2017)
Net sales	52,311	63,368
Cost of sales	31,391	38,705
Gross profit	20,919	24,662
Selling, general and administrative expenses	19,289	22,588
Operating income	1,630	2,074
Non-operating income		
Dividends income	232	268
Other	310	237
Total non-operating income	542	505
Non-operating expenses		
Interest expenses	107	173
Bond issuance cost	-	112
Other	67	47
Total non-operating expenses	174	333
Ordinary income	1,998	2,247
Extraordinary income		
Gain on sales of noncurrent assets	6	6
Other	0	-
Total extraordinary income	7	6
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	14	33
Other	1	-
Total extraordinary losses	16	33
Income before income taxes and minority interests	1,989	2,220
Income taxes-current	1,234	1,364
Income taxes-deferred	(463)	(442)
Total income taxes	770	922
Net income	1,218	1,297
Net income attributable to the noncontrolling interest	134	134
Net income attributable to owners of the parent	1,084	1,163

(Consolidated Quarterly Statements of Comprehensive Income)
(For the Three Months Ended June 30, 2017 and 2016)

(Millions of Yen)

	FY2017 (Apr. 1, 2016 – June 30, 2016)	FY2018 (Apr. 1, 2017 – June 30, 2017)
Net income	1,218	1,297
Other comprehensive income		
Valuation difference on available-for-sale securities	(273)	931
Deferred gains or losses on hedges	(505)	122
Foreign currency translation adjustment	(3,485)	(2,195)
Remeasurements of defined benefit plans	(2)	15
Share of other comprehensive income of associates accounted for using equity method	(193)	-
Total other comprehensive income	(4,461)	(1,126)
Comprehensive income	(3,242)	171
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	(2,800)	508
Comprehensive income attributable to noncontrolling interest	(441)	(337)

(3) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Material Changes in Subsidiaries during the Three Months Ended June 30, 2017)

Due to Takara Bio Inc.'s wholly owned subsidiary Takara Bio USA Holdings Inc. acquiring shares of WaferGen Bio-systems, Inc., WaferGen Bio-systems, Inc. and its subsidiaries WaferGen BioSystems Europe S.a.r.l. and WaferGen, Inc. are included in the scope of consolidation for the three months ended June 30, 2017. Note that during this period WaferGen Bio-systems, Inc. qualifies as a specified subsidiary of the Company.

In addition, due to the acquisition of shares of Rubicon Genomics, Inc., this company had been included in the scope of consolidation as a specified subsidiary for the three months ended June 30, 2017. However, as Rubicon Genomics, Inc. was extinguished due to an absorption-type merger in which the consolidated subsidiary Takara Bio USA, Inc. was the surviving company, Rubicon Genomics, Inc. has been excluded from the scope of consolidation for the three months ended June 30, 2017.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2016 to June 30, 2016)

1. Net sales and Income (Loss) by Reported Segment

<Information for the three months ended June 30, 2016 stated based on post-change classifications>

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	34,226	7,312	6,077	47,617	4,694	52,311	0	52,311
Intersegment	9	120	228	357	4,427	4,784	(4,784)	-
Total	34,235	7,432	6,306	47,974	9,121	57,095	(4,784)	52,311
Segment income (loss)	(85)	606	643	1,164	419	1,583	46	1,630

Notes: 1. Other includes business segments that are not part of reported segments, such as the Company's real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.
   (1) Net sales to external customers are income from business contracting recorded at the Company.
   (2) Segment income (loss) comprises intersegment eliminations of ¥61 million and income of the Company not allocated to business segments of ¥-15million.

3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Non-current Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2017, to June 30, 2017)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	36,018	16,354	6,175	58,547	4,820	63,368	0	63,368
Intersegment	10	96	180	287	4,814	5,101	(5,101)	-
Total	36,029	16,450	6,355	58,835	9,634	68,470	(5,101)	63,368
Segment income	151	960	262	1,374	753	2,128	(53)	2,074

Notes: 1. Other includes business segments that are not part of reported segments, such as the Company's real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.
   (1) Net sales to external customers are income from business contracting recorded at the Company.
   (2) Segment income comprises intersegment eliminations of ¥24 million and income of the Company not allocated to business segments of ¥77 million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Matters concerning Changes to Reporting Segments

In accordance with the spinning off of the overseas business of Takara Shuzo Co., Ltd., the Company's consolidated subsidiary, on July 3 2017 and the establishment of Takara Shuzo International Co., Ltd., the Company changed its reporting segment to Takara Shuzo, Takara Shuzo International Group, and Takara Bio Group starting from the three months ended June 30, 2017.

The segment information for the three months ended June 30, 2017 discloses information prepared based on the post-change segments.

3. Information on Impairment Loss on Non-current Assets, Goodwill, etc. by Reportable Segment

(Significant Changes to the Amount of Goodwill)

In the Takara Bio Group segment, goodwill was recorded due to the acquisition of shares in WaferGen Bio-systems, Inc. and Rubicon Genomics, Inc. by the Takara Bio Inc.'s wholly owned subsidiary Takara Bio USA Holdings Inc. The increase in goodwill due to this event in the three months ended June 30, 2017 was ¥7,709 million. Note that as the allocation of the acquisition cost has not been completed, this is a tentatively calculated amount.

平成30年3月期
第1四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the First Quarter Ended June 30, 2017

1. 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   - グループ別要約損益計算書
     Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造
   Takara Shuzo Co.,Ltd.
   - 要約損益計算書
     Statements of Income (Summary)

3. 宝酒造インターナショナルグループ
   Takara Shuzo International Group
   - 要約損益計算書
     Statements of Income (Summary)

4. タカラバイオグループ
   Takara Bio Group
   - 要約損益計算書
     Statements of Income (Summary)

5. 6年間の財務サマリー(グループ別)
   Six-Year Financial Summary by Business Group

6. 平成30年3月期第1四半期　参考資料
   Reference Data for the First Quarter Ended June 30, 2017

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

IR部 Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5194
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　IR部

Takara Holdings Inc. Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5194

E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	平成29年3月期 第1四半期	平成30年3月期 第1四半期 Apr. 1, 2017 - Jun. 30, 2017		
	実績(a) FY2017 (1stQ) Actual (a)	実績(b) FY2018 (1stQ) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
宝酒造 Takara Shuzo Group	34,235	36,029	1,793	105.2%
宝酒造インターナショナルグループ Takara Shuzo International Group	7,432	16,450	9,018	221.3%
タカラバイオ グループ Takara Bio Group	6,306	6,355	48	100.8%
その他 Other	9,121	9,634	513	105.6%
調整額 Adjustment	△ 4,784	△ 5,101	△ 317	―
売上高 Net sales	52,311	63,368	11,057	121.1%
売上原価 Cost of sales	31,391	38,705	7,313	123.3%
売上総利益 Gross profit	20,919	24,662	3,743	117.9%
運送費、保管料 Transportation and storage	2,097	2,319	222	110.6%
広告宣伝費 Advertising	894	861	△ 33	96.3%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	8,370	8,886	515	106.2%
研究開発費 Research and development	1,045	1,201	156	114.9%
管理費、その他 Other, net	6,881	9,319	2,437	135.4%
販売費及び一般管理費 SG&A expenses	19,289	22,588	3,298	117.1%
宝酒造 Takara Shuzo Group	△ 85	151	236	―
宝酒造インターナショナルグループ Takara Shuzo International Group	606	960	354	158.4%
タカラバイオ グループ Takara Bio Group	643	262	△ 380	40.8%
その他 Other	419	753	334	179.6%
調整額 Adjustment	46	△ 53	△ 99	―
営業利益(△:損失) Operating income(Δ:loss)	1,630	2,074	444	127.3%
受取利息・配当金 Interest and Dividends income	280	305	24	108.8%
その他営業外収益 Other, net	261	200	△ 61	76.5%
営業外収益 Non-operating income	542	505	△ 36	93.2%
支払利息 Interest and discounts expenses	107	173	66	162.2%
その他営業外費用 Other, net	67	159	92	237.4%
営業外費用 Non-operating expenses	174	333	158	191.2%
経常利益(△:損失) Ordinary income(Δ:loss)	1,998	2,247	248	112.4%
特別利益 Extraordinary gain	7	6	△ 1	85.1%
特別損失 Extraordinary loss	16	33	16	197.0%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	1,989	2,220	231	111.6%
法人税、住民税及び事業税 Current income taxes / 法人税等調整額 Deferred income taxes	770	922	152	119.7%
四半期純利益(△:損失) Net income(Δ:loss)	1,218	1,297	79	106.5%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	134	134	△ 0	99.8%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	1,084	1,163	79	107.3%
設備投資額(有形・無形) Capital expenditures	681	946	264	138.8%
減価償却費(有形・無形) Depreciation and Amortization	1,245	1,522	276	122.2%
のれん償却額 Amortization of goodwill	122	194	72	159.1%

営業外収益 Non-operating income	受取利息37、受取配当金268、生命保険配当金66 など Interest income 37, Dividends income 268, Dividend income of life insurance 66, etc.
営業外費用 Non-operating expenses	支払利息107、社債利息65、社債発行費112 など Interest expenses 107, Interest on bonds 65, Bond issuance cost 112, etc.
特別利益 Extraordinary gain	固定資産売却益6 Gain on sales of noncurrent assets 6
特別損失 Extraordinary loss	固定資産除売却損33など Loss on sales and retirement of noncurrent assets 33, etc.

2. 宝酒造 :Takara Shuzo Co., Ltd.

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成29年3月期 第1四半期	平成30年3月期 第1四半期 Apr. 1, 2017 - Jun. 30, 2017		
	実績(a) FY2017 (1stQ) Actual (a)	実績(b) FY2018 (1stQ) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
焼酎 Shochu	13,987	14,089	101	100.7%
清酒 Sake	3,888	4,214	326	108.4%
ソフトアルコール飲料 Light-alcohol refreshers	7,364	8,469	1,105	115.0%
その他酒類 Other liquors	1,722	1,641	△ 81	95.3%
本みりん Hon Mirin	3,327	3,359	32	101.0%
その他調味料 Other seasonings	2,175	2,306	131	106.0%
原料用アルコール等 Raw alcohol	1,769	1,947	177	110.1%
売上高 Net sales	34,235	36,029	1,793	105.2%
売上原価 Cost of sales	20,797	21,665	868	104.2%
売上総利益 Gross profit	13,438	14,363	925	106.9%
運送費、保管料 Transportation and storage	1,639	1,761	121	107.4%
広告宣伝費 Advertising	735	735	0	100.1%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	8,066	8,561	494	106.1%
研究開発費 Research and development	85	88	2	102.6%
管理費、その他 Other, net	2,996	3,065	69	102.3%
販売費及び一般管理費 SG&A expenses	13,523	14,212	688	105.1%
営業利益（△：損失） Operating income(Δ:loss)	△ 85	151	236	—
営業外収益 Non-operating income	891	1,198	307	134.5%
営業外費用 Non-operating expenses	64	43	△ 20	67.8%
経常利益（△：損失） Ordinary income(Δ:loss)	741	1,305	564	176.1%
特別利益 Extraordinary gain	—	—	—	—
特別損失 Extraordinary loss	10	20	10	196.3%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	730	1,285	554	175.8%
法人税、住民税及び事業税 Current income taxes	10	92	81	877.4%
法人税等調整額 Deferred income taxes				
四半期純利益（△：損失） Net income(Δ:loss)	720	1,192	472	165.5%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	—	—	—	—
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	720	1,192	472	165.5%
設備投資額（有形・無形） Capital expenditures	211	315	104	149.5%
減価償却費（有形・無形） Depreciation and Amortization	516	516	△ 0	100.0%

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成29年3月期 第1四半期	平成30年3月期 第1四半期 Apr. 1, 2017 - Jun. 30, 2017		
	実績(a) FY2017 (1stQ) Actual (a)	実績(b) FY2018 (1stQ) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
海外酒類事業 Overseas Alcoholic beverages business	2,264	2,340	76	103.4%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	5,311	14,516	9,204	273.3%
連結消去 Elimination	△ 142	△ 406	△ 263	―
売上高 Net sales	7,432	16,450	9,018	221.3%
売上原価 Cost of sales	4,989	11,683	6,693	234.2%
売上総利益 Gross profit	2,443	4,767	2,324	195.1%
運送費、保管料 Transportation and storage	338	459	120	135.5%
広告宣伝費 Advertising	16	10	△ 5	65.2%
販売促進費 Sales promotion	103	109	6	106.2%
管理費、その他 Other, net	1,378	3,227	1,849	234.1%
販売費及び一般管理費 SG&A expenses	1,837	3,807	1,970	207.2%
海外酒類事業 Overseas Alcoholic beverages business	278	379	101	136.5%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	557	830	272	148.9%
共通 Eliminations/Corporate	△ 132	△ 156	△ 23	―
調整額 Adjustment	△ 97	△ 93	3	―
営業利益（△：損失） Operating income(Δ:loss)	606	960	354	158.4%
営業外収益 Non-operating income	117	61	△ 55	52.6%
営業外費用 Non-operating expenses	11	79	67	692.0%
経常利益（△：損失） Ordinary income(Δ:loss)	711	942	230	132.4%
特別利益 Extraordinary gain	1	1	0	120.9%
特別損失 Extraordinary loss	1	0	△ 1	3.7%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	711	944	232	132.7%
法人税、住民税及び事業税 Current income taxes	215	314	98	146.0%
法人税等調整額 Deferred income taxes				
四半期純利益（△：損失） Net income(Δ:loss)	496	630	134	127.0%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	7	127	120	1708.0%
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	488	502	13	102.8%

設備投資額（有形・無形） Capital expenditures	154	322	167	208.3%
減価償却費（有形・無形） Depreciation and Amortization	146	230	84	157.6%
のれん償却額 Amortization of goodwill	78	85	6	107.8%

4. タカラバイオグループ :Takara Bio Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成29年3月期 第1四半期	平成30年3月期 第1四半期 Apr. 1, 2017 - Jun. 30, 2017		
	実績(a) FY2017 (1stQ) Actual (a)	実績(b) FY2018 (1stQ) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
研究用試薬 Research reagents	4,737	4,660	△ 77	98.4%
理化学機器 Scientific instruments	509	472	△ 36	92.8%
受託・その他 Contracted service and other	566	753	187	133.1%
バイオ産業支援　計 Bioindustry	5,813	5,886	73	101.3%
遺伝子医療 Gene therapy	―	―	―	―
医食品バイオ AgriBio	493	468	△ 24	94.9%
売上高 Net sales	6,306	6,355	48	100.8%
売上原価 Cost of sales	2,439	2,245	△ 194	92.0%
売上総利益 Gross profit	3,866	4,109	243	106.3%
運送費、保管料 Transportation and storage	146	143	△ 3	97.8%
広告宣伝費 Advertising	24	19	△ 5	79.4%
販売促進費 Sales promotion	214	222	7	103.7%
研究開発費 Research and development	950	1,103	153	116.1%
管理費、その他 Other, net	1,887	2,358	470	124.9%
販売費及び一般管理費 SG&A expenses	3,223	3,846	623	119.4%
バイオ産業支援　計 Bioindustry	1,456	1,165	△ 290	80.0%
遺伝子医療 Gene therapy	△ 373	△ 419	△ 45	―
医食品バイオ AgriBio	△ 15	△ 24	△ 8	―
共通 Eliminations/Corporate	△ 424	△ 459	△ 35	―
営業利益（△：損失） Operating income(Δ:loss)	643	262	△ 380	40.8%
営業外収益 Non-operating income	43	52	9	121.3%
営業外費用 Non-operating expenses	32	27	△ 5	84.1%
経常利益（△：損失） Ordinary income(Δ:loss)	653	287	△ 366	44.0%
特別利益 Extraordinary gain	2	0	△ 2	9.0%
特別損失 Extraordinary loss	3	9	5	246.2%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	652	278	△ 374	42.7%
法人税、住民税及び事業税 Current income taxes	368	253	△ 114	68.9%
法人税等調整額 Deferred income taxes				
四半期純利益（△：損失） Net income(Δ:loss)	283	24	△ 259	8.5%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	△ 1	1	2	―
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	285	22	△ 262	8.0%

設備投資額（有形・無形） Capital expenditures	211	174	△ 36	82.6%
減価償却費（有形・無形） Depreciation and Amortization	436	580	143	132.9%
のれん償却額 Amortization of goodwill	43	109	65	253.1%

5. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	平成29年3月期 第1四半期 FY2017 (1stQ)	平成30年3月期 第1四半期 FY2018 (1stQ)	前期対比 Change from FY2017(1stQ) 増減 Change	比 YOY%
売上高	Net sales	47,349	46,953	50,025	50,938	52,311	63,368	11,057	121.1%
売上原価	Cost of sales	29,075	29,570	31,031	31,323	31,391	38,705	7,313	123.3%
（売上高原価率）	(Ratio to Net sales)	61.4%	63.0%	62.0%	61.5%	60.0%	61.1%	+1.1pt	–
売上総利益	Gross profit	18,273	17,382	18,994	19,615	20,919	24,662	3,743	117.9%
販売費及び一般管理費	SG&A expenses	17,212	17,624	17,811	18,966	19,289	22,588	3,298	117.1%
（売上高販管費率）	(Ratio to Net sales)	36.4%	37.5%	35.6%	37.2%	36.9%	35.6%	-1.2pt	–
営業利益（△：損失）	Operating income(Δ:loss)	1,061	Δ 241	1,182	649	1,630	2,074	444	127.3%
（売上高営業利益率）	(Ratio to Net Sales)	2.2%	–	2.4%	1.3%	3.1%	3.3%	+0.2pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	8,170	8,221	8,198	8,169	8,370	8,886	515	106.2%
（売上高販促費率）	(Ratio to Net sales)	17.3%	17.5%	16.4%	16.0%	16.0%	14.0%	-2.0pt	–
研究開発費	R&D expenses	737	792	792	1,103	1,045	1,201	156	114.9%
（売上高研究開発費率）	(Ratio to Net sales)	1.6%	1.7%	1.6%	2.2%	2.0%	1.9%	-0.1pt	–
設備投資額（有形・無形）	Capital expenditures	998	1,777	2,012	365	681	946	264	138.8%
減価償却費（有形・無形）	Depreciation and Amortization	999	996	1,012	1,216	1,245	1,522	276	122.2%
のれん償却額	Amortization of goodwill	68	75	116	133	122	194	72	159.1%

宝酒造 :Takara Shuzo Co., Ltd.

（百万円 :Millions of Yen）

		平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	平成29年3月期 第1四半期 FY2017 (1stQ)	平成30年3月期 第1四半期 FY2018 (1stQ)	前期対比 Change from FY2017(1stQ) 増減 Change	比 YOY%
売上高	Net sales	–	–	–	–	34,235	36,029	1,793	105.2%
売上原価	Cost of sales	–	–	–	–	20,797	21,665	868	104.2%
（売上高原価率）	(Ratio to Net sales)	–	–	–	–	60.7%	60.1%	-0.6pt	–
売上総利益	Gross profit				–	13,438	14,363	925	106.9%
販売費及び一般管理費	SG&A expenses				–	13,523	14,212	688	105.1%
（売上高販管費率）	(Ratio to Net sales)				–	39.5%	39.4%	-0.1pt	–
営業利益（△：損失）	Operating income(Δ:loss)				–	Δ 85	151	236	–
（売上高営業利益率）	(Ratio to Net sales)				–	–	0.4%	–	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.				–	8,066	8,561	494	106.1%
（売上高販促費率）	(Ratio to Net sales)				–	23.6%	23.8%	+0.2pt	–
設備投資額（有形・無形）	Capital expenditures	–	–	–	–	211	315	104	149.5%
減価償却費（有形・無形）	Depreciation and Amortization	–	–	–	–	516	516	Δ 0	100.0%

平成30年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

		平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	平成29年3月期 第1四半期 FY2017 (1stQ)	平成30年3月期 第1四半期 FY2018 (1stQ)	前期対比 Change from FY2017(1stQ) 増減 Change	比 YOY%
売上高	Net sales	–	–	–	–	7,432	16,450	9,018	221.3%
売上原価	Cost of sales	–	–	–	–	4,989	11,683	6,693	234.2%
（売上高原価率）	(Ratio to Net sales)	–	–	–	–	67.1%	71.0%	+3.9pt	–
売上総利益	Gross profit				–	2,443	4,767	2,324	195.1%
販売費及び一般管理費	SG&A expenses				–	1,837	3,807	1,970	207.2%
（売上高販管費率）	(Ratio to Net sales)				–	24.7%	23.1%	-1.6pt	–
営業利益（△：損失）	Operating income(Δ:loss)				–	606	960	354	158.4%
（売上高営業利益率）	(Ratio to Net sales)				–	8.2%	5.8%	-2.3pt	–
のれん償却後営業利益（△：損失）	Operating income after amortization of goodwill				–	527	875	347	166.0%
（のれん償却後営業利益率）	(Ratio to Net sales)				–	7.1%	5.3%	-1.8pt	–
設備投資額（有形・無形）	Capital expenditures	–	–	–	–	154	322	167	208.3%
減価償却費（有形・無形）	Depreciation and Amortization	–	–	–	–	146	230	84	157.6%
のれん償却額	Amortization of goodwill	–	–	–	–	78	85	6	107.8%

平成30年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	平成29年3月期 第1四半期 FY2017 (1stQ)	平成30年3月期 第1四半期 FY2018 (1stQ)	前期対比 Change from FY2017(1stQ) 増減 Change	比 YOY%
売上高	Net sales	4,104	4,170	4,779	5,761	6,306	6,355	48	100.8%
売上原価	Cost of sales	1,569	1,977	2,024	2,439	2,439	2,245	Δ 194	92.0%
（売上高原価率）	(Ratio to Net sales)	38.2%	47.4%	42.4%	42.3%	38.7%	35.3%	-3.4pt	–
売上総利益	Gross profit	2,535	2,192	2,754	3,322	3,866	4,109	243	106.3%
販売費及び一般管理費	SG&A expenses	2,360	2,551	2,689	3,210	3,223	3,846	623	119.4%
（売上高販管費率）	(Ratio to Net sales)	57.5%	61.2%	56.3%	55.7%	51.1%	60.5%	+9.4pt	–
営業利益（△：損失）	Operating income(Δ:loss)	175	Δ 358	65	111	643	262	Δ 380	40.8%
（売上高営業利益率）	(Ratio to Net sales)	4.3%	–	1.4%	1.9%	10.2%	4.1%	-6.1pt	–
研究開発費	R&D expenses	646	704	703	1,020	950	1,103	153	116.1%
（売上高研究開発費率）	(Ratio to Net sales)	15.7%	16.9%	14.7%	17.7%	15.1%	17.4%	+2.3pt	–
設備投資額（有形・無形）	Capital expenditures	475	1,390	782	90	211	174	Δ 36	82.6%
減価償却費（有形・無形）	Depreciation and Amortization	263	271	269	392	436	580	143	132.9%
のれん償却額	Amortization of goodwill	31	32	30	44	43	109	65	253.1%

（参考）宝酒造グループ :Reference Data for the Takara Shuzo Group

（百万円 :Millions of Yen）

		平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	平成29年3月期 第1四半期 FY2017 (1stQ)	平成30年3月期 第1四半期 FY2018 (1stQ)	前期対比 Change from FY2017(1stQ) 増減 Change	比 YOY%
売上高	Net sales	42,291	41,978	44,370	44,231	45,124	–	–	–
売上原価	Cost of sales	27,025	27,242	28,623	28,466	28,622			
売上総利益	Gross profit	15,266	14,735	15,746	15,764	16,501			
販売費及び一般管理費	SG&A expenses	14,680	14,869	14,916	15,384	15,658			
営業利益（△：損失）	Operating income(Δ:loss)	585	Δ 134	830	380	843			
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	7,942	7,977	7,970	7,927	8,131			
設備投資額（有形・無形）	Capital expenditures	331	369	1,206	273	422			
減価償却費（有形・無形）	Depreciation and Amortization	703	683	705	765	749			
のれん償却額	Amortization of goodwill	37	43	85	88	78	–	–	–

平成29年3月期までの旧セグメントです。
This is an old segment until the fiscal year ended March 2017.

6. 平成30年3月期第1四半期 参考資料 :Reference Data for the First Quarter Ended June 30, 2017

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	平成29年3月期 第1四半期	平成30年3月期 第1四半期 Apr. 1, 2017 - Jun. 30, 2017	
	実績(a) FY2017 (1stQ) Actual (a)	実績(b) FY2018 (1stQ) Actual (b)	前期差 Change(b-a)
米ドル : US dollar	115.33	113.60	△ 1.73
ポンド: Pound	165.01	140.74	△ 24.27
ユーロ: Euro	127.11	121.05	△ 6.06
人民元: Yuan	17.60	16.56	△ 1.04
100ウォン: 100 Won	9.60	9.87	0.27
インドルピー: Rupee	1.71	1.70	△ 0.01
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	13.64	12.73	△ 0.91
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	82.18	80.23	△ 1.95
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	―	86.17	―

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2017(1stQ)
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	△ 676
うち宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Net sales of Takara Shuzo International Group	△ 561
海外酒類事業 Overseas Alcoholic beverages business	△ 139
海外日本食材卸事業 Japanese food wholesale business in overseas markets	△ 428
連結消去 Elimination	5
うちタカラバイオグループ Net sales of Takara Bio Group	△ 119
研究用試薬 Research reagents	△ 106
理化学機器 Scientific instruments	0
受託・その他 Contracted service and other	△ 12
バイオ産業支援 計 Bioindustry	△ 119
遺伝子医療 Gene Therapy	―
医食品バイオ AgriBio	―

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	平成29年3月期第1四半期 実績 FY2017(1stQ) Actual			平成30年3月期第1四半期 実績 FY2018(1stQ) Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo Co., Ltd.	34,235	―	―	36,029	―	―
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	7,432	7,313	98.4%	16,450	16,349	99.4%
タカラバイオグループ Takara Bio Group	6,306	3,968	62.9%	6,355	3,940	62.0%
その他および調整額 Other / Adjustment	4,336	―	―	4,532	―	―
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	52,311	11,281	21.6%	63,368	20,289	32.0%

③ 海外主要子会社の業績 :Financial Forecast of major overseas subsidiaries

		平成29年3月期第1四半期 実績 FY2017(1stQ) Actual		平成30年3月期第1四半期 実績 FY2018(1stQ) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	7,607	580	7,986	1,006
Takara Sake USA Inc.	百 万 円 :Millions of Yen	877	66	907	114
宝酒造食品	千 元 :Thousands of Yuan	9,763	Δ 355	11,059	Δ 252
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	171	Δ 6	183	Δ 4
トマーチン	千 ポ ン ド :Thousands of Pound	3,062	281	4,359	933
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	505	46	613	131
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	4,525	1,740	4,246	1,600
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	521	200	482	181
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	31,352	3,436	35,448	4,106
FOODEX Group	百 万 円 :Millions of Yen	3,985	436	4,291	497
タザキフーズ	千 ポ ン ド :Thousands of Pound	8,035	732	9,084	68
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	1,325	120	1,278	9
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	―	―	70,801	2,841
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	―	―	8,043	322
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	―	―	10,482	12
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	―	―	903	1
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S.	千 ユ ー ロ :Thousands of Euro	4,884	672	4,654	305
Takara Bio Europe S.A.S.	百 万 円 :Millions of Yen	620	85	563	36
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟAB	千 SEK :Thousands of Sweden Krona	6,736	Δ 4,317	9,508	Δ 253
Takara Bio Europe AB	百 万 円 :Millions of Yen	91	Δ 58	121	Δ 3
宝生物工程(大連)	千 元 :Thousands of Yuan	75,439	32,071	49,442	11,440
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	1,327	564	818	189
宝日医生物技術(北京)	千 元 :Thousands of Yuan	26,043	560	64,400	4,807
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	458	9	1,066	79
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	2,023	247	2,598	299
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	194	23	256	29
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	46,587	Δ 434	50,201	Δ 1,219
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	79	Δ 0	85	Δ 2
タカラバイオUSA	千 US ドル :Thousands of US dollar	19,891	4,652	22,253	3,252
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	2,294	536	2,527	369

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo Co., Ltd.

(百万円 :Millions of Yen)

	対前期増減 Change from FY2017(1stQ)		
	増減計 Total Change	数量差 Change in quantities	単価差 Change in unit price
売上総利益 計 Gross profit	+925	+729	+195
(主な内訳)			
焼酎 Shochu	+53	Δ 54	+108
清酒 Sake	+86	+93	Δ 7
ｿﾌﾄｱﾙｺｰﾙ飲料 Light-alcohol refreshers	+573	+545	+28
本みりん Hon Mirin	+59	+18	+40
(参考)原価コストダウン Reference :Cost reduction	Δ 52	※上記数量差および単価差に含む *Included in changes above	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statemnets of Income of Takara Holdings Inc. (Summary) (p.1)

	平成29年3月期第1四半期 実績 FY2017(1stQ) Actual		平成30年3月期第1四半期 実績 FY2018(1stQ) Actual	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	4,598	182	4,856	389
宝ヘルスケア Takara Healthcare	457	Δ 24	414	13
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	116	98	116	100
その他 Other	3,948	163	4,248	250
「その他」計 Total "Other"	9,121	419	9,634	753